Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
complicated intra-abdominal infections
You may not be if
infections limited to hollow viscus
ischemic bowel disease without perforation
acute suppurative cholangitis
acute necrotizing pancreatitis
pts to undergo stated abdominal repair, open abdomen technique or marsupialization
Apache II \>25
Clareo Health | Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
